Please login to the form below

Not currently logged in
Email:
Password:

Voltarra names new CEO

Richard Becker has experience at Alcon, Merck, Novartis, OSI, Bayer and BASF

Voltarra Pharmaceuticals has appointed Richard Becker as CEO.

Becker brings more than 20 years' experience to the US biopharma, including senior commercial roles at Alcon, Merck, Novartis, OSI, Bayer and BASF.

In his new role, he leads a company with a pipeline of drugs for rheumatology, central nervous system oncology and immunology.

Voltarra's lead product is VOLT01, which is in late-stage trials for the treatment of osteoarthritis.

Becker said: “The broad portfolio will allow Voltarra Pharmaceuticals to capitalise on development synergies and favourably position the company with external customers. We are extremely excited about the pipeline as well as future plans for a partner in taking VOLT01 to the next stage.”

19th November 2013

From: Sales

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Difference Collective

Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...

Latest intelligence

Main image1
Global leaders in digital channels
Exploring why UK field teams are global leaders in digital channels is key to better understanding the changes in omnichannel engagement...
Kate Shaw reflects on Innovative Trials' first US office openings
On Thanksgiving, Kate Shaw, Founder and CEO of Innovative Trials, reflects on the company first US office opening...
Meeting1
Reimagining strategy development for a hybrid workforce
By Janice MacLennan...